NCT05899907 is a Phase 4 clinical trial of Telitacicept in Lupus Erythematosus, Systemic, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT05899907?

NCT05899907 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT05899907?

Interventions in NCT05899907: Telitacicept, Standard of Care.

What condition does NCT05899907 study?

NCT05899907 studies Lupus Erythematosus, Systemic.

Is NCT05899907 still recruiting?

NCT05899907 is currently status unknown. Last updated 12 June 2023.

Last reviewed 2023-06-12 · How we verify

NCT05899907

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Telitacicept in Early SLE

Status unknown Phase 4 Last updated 12 June 2023

What this trial tests

Phase 4 trial testing Telitacicept in Lupus Erythematosus, Systemic in 180 participants. Status unknown.

Timeline

1 September 2022

Primary endpoint
1 March 2025

1 September 2025

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	180
Start date	1 September 2022
Primary completion	1 March 2025
Estimated completion	1 September 2025
Sites	20 locations across China

Drugs / interventions tested

Telitacicept — full drug profile →
Standard of Care

Conditions studied

Lupus Erythematosus, Systemic — all drugs for Lupus Erythematosus, Systemic →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 65, any sex, with Lupus Erythematosus, Systemic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with early stage of SLE .

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Systemic lupus erythematosus: pathogenesis and targeted therapy.
Su X, Yu H, Lei Q, Chen X, et al · · 2024 · cited 33× · PMID 39472388 · DOI 10.1186/s43556-024-00217-8

Verify or expand the search:

Other trials of Telitacicept

Trials testing the same drug.

NCT07522099 — Chinese Adults With Kidney Disease · Phase 2 · recruiting
NCT07495033 — Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related I · Phase 3 · not yet recruiting
NCT07249632 — A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) · Phase 3 · recruiting
NCT07052981 — Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculiti · Phase 3 · not yet recruiting
NCT06375005 — Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis · Phase 2 · recruiting

Other recruiting trials for Lupus Erythematosus, Systemic

Currently open trials in the same condition.

NCT07424261 — NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care · recruiting
NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
NCT07330245 — Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab. · recruiting
NCT07015983 — A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I · Phase 2 · recruiting
NCT06881290 — Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus · Phase 1 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05899907 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 12 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05899907.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing